Get to know our clinical trials

First human trial to assess the safety and efficacy of BAY 3547926 in participants with advanced liver cancer.

THE PURPOSE OF THIS TRIAL IS TO DETERMINE WHETHER THE NEW DRUG BAY 3547926 CAN BE SAFELY ADMINISTERED TO PARTICIPANTS, TO IDENTIFY THE OPTIMAL DOSE, AND TO INVESTIGATE HOW THIS NEW DRUG WORKS IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA.

Imagen del Dr. Bruno Sangro, especialista en Medicina Interna. El Dr. Sangro trabaja en la Unidad de Hepatología de la Clínica Universidad de Navarra. Se dedica preferencialmente al estudio y tratamiento de las enfermedades hepáticas y los tumores del área hepática y biliar.
Dr. Bruno Sangro Curriculum
Director Hepatology Unit
Navarre headquarters
Madrid headquarters
Cancer Center
Liver and Pancreatic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • FIRST HUMAN TRIAL TO ASSESS THE SAFETY AND EFFICACY OF BAY 3547926 IN PARTICIPANTS WITH ADVANCED LIVER CANCER.
  • Code EudraCT: 2024-516615-25-00
  • Protocol number: BAY 3547926/ 22262
  • Promoter: Bayer Hispania S.L
  • Molecule/Drug: BAY 3547926
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION